6K: Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
false
פרפל ביוטק בע"מ
2
380
PURPLE BIOTECH LTD
Corporation no:
520031238
12724
Israel Securities Authority
Tel Aviv Stock Exchange
C002
(
Public
)
Reported via MAGNA:
19/04/2021
www.isa.gov.il
www.tase.co.il
Reference:
2021-02-065685
Time of broadcast:
14:00
14:00
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
6K: Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
ea139635-6k_purplebiotechEDAGR3_Bannerless_isa.pdf
החברה ,תציג מנגנון פעולה נוסף של NT219 בכנס השנתי של AACR 6K
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
NASDAQ CM
Date of revision of form structure:
03/03/2021
Address:
Oppenheimer, Science Park
4
,
Rehovot
7670104
,
Israel
Tel:
03-9333121
,
03-9311321
Fax:
03-5097196
E-mail address:
ir@purple-biotech.com
Company site:
www.kitovpharma.com
Previous names of reporting entity:
KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory:
Masas Ludmer Adi
Position of Signatory in the reporting corporation:
Company Controller
Name of Employer Company:
Address:
Menachem Begin Drive
132
,
Tel Aviv
6701101
Telephone:
03-9333121
Facsimile:
03-5097196
E-mail:
adim@kitovpharma.com
1
Israel